MetaVia Inc. is trading 34% up at $3.28 in pre-market, sharply rebounding from a week-long slide that saw shares close at $2.45 on June 04, 2026.
- The move follows heightened attention on the company’s obesity and metabolic therapies pipeline.
- Investors are focused on upcoming financing, listing risks, and a key shareholder vote highlighted in recent news coverage.